Cellectis S.A. SEC Filings

Cellectis S.A. reported unaudited results for the six months ended June 30, 2026. Revenues were $11.0 million, mainly from the AstraZeneca joint research collaboration, down from $27.4 million a year earlier, and total revenues and other income were $14.5 million.

Research and development expenses rose to $52.2 million and selling, general and administrative costs to $11.3 million, leading to an operating loss of $48.7 million. A net financial gain of $9.2 million, driven largely by fair value gains on European Investment Bank warrants and markedly lower foreign-exchange losses, partially offset operating losses.

The period’s net loss was $39.6 million, or $0.39 per basic and diluted share, compared with a $41.9 million loss in the prior-year period. At June 30, 2026, cash and cash equivalents were $35.6 million and fixed-term deposits classified as current financial assets were $131.1 million. The company states these resources are sufficient to fund operations for at least twelve months after board approval of these financial statements.

Cellectis S.A., a clinical-stage biotechnology company focused on gene-edited cell and gene therapies, stated it will report second quarter 2026 financial results for the quarter ended June 30, 2026 on Thursday, August 6, 2026 after the close of the US market.

The company indicated it will not host a conference call for these results and directed investors to its website and investor relations contacts for the press release and any questions. Cellectis uses an allogeneic approach to CAR T immunotherapies and is listed on Nasdaq and Euronext Growth.

Cellectis S.A. filed an amended Form 6-K to correct a clerical error in the previously reported voting results of its Combined General Meeting of Shareholders held on June 25, 2026. The vote tallies themselves were already accurate and remain unchanged.

The amendment clarifies that Resolution 30, a delegation of authority to increase share capital for members of a company savings plan, was in fact rejected, not carried. Shareholders voted 57,625,365 votes (85.19%) against and 10,014,708 votes (14.81%) for this resolution. All other resolutions, including approval of 2025 financial statements, multiple capital increase delegations, share buyback authority, and equity-based compensation authorizations, were correctly reported as carried.

Cellectis filed a Form 6-K to report the results of its shareholders general meeting held on June 25, 2026 in Paris. At this meeting, about 55.84% of voting rights were exercised. Resolutions 1 through 29 were adopted and resolution 30 was rejected, in line with the board of directors’ recommendations. Detailed voting results are available on the company’s website. Cellectis is a clinical-stage biotechnology company developing gene-edited, off-the-shelf CAR T-cell therapies and other gene therapies, with shares listed on Nasdaq and Euronext Growth.

Cellectis S.A. reported the results of its Combined General Meeting of Shareholders held on June 25, 2026. Shareholders approved the 2025 annual and consolidated financial statements, allocation of results, and review of regulated agreements, with around 99.9% of votes in favor on the core financial items.

The meeting renewed four directors, including Jean‑Pierre Garnier and Cécile Chartier, and authorized the Board to repurchase shares and cancel repurchased shares, each with more than 99% support. A broad set of capital increase delegations was approved, many with cancellation of preferential subscription rights for targeted investor categories, including an equity financing program on the U.S. market through an “at‑the‑market” facility.

Shareholders also approved authorizations for stock options and free share grants, as well as related caps, and amended bylaws to reflect new legal provisions. One item, a capital increase reserved for members of a company savings plan, was rejected, receiving about 14.8% votes in favor and 85.2% against. Quorum reached 55.840%, with 46,175,805 shares represented, or 45.858% of the share capital.

Cellectis reported new clinical data for its allogeneic CAR-T candidates lasme-cel and eti-cel at the EHA 2026 congress. In the BALLI-01 Phase 1 trial’s target Phase 2 population for relapsed/refractory B-ALL, lasme-cel achieved a 100% overall response rate (7/7) with 57% (4/7) complete remission or complete remission with incomplete count recovery, and 75% of these responders reached MRD-negative status before all proceeded to stem cell transplant.

Lasme-cel showed a manageable safety profile, with grade ≥3 cytokine release syndrome in 4% of patients, immune effector cell-associated neurotoxicity in 4%, and IEC-HS in 2%, all resolving. In NATHALI-01 for relapsed/refractory B-NHL, eti-cel produced an 88% overall response rate and 63% complete response rate in the optimal dose cohort, while analyses linked higher alemtuzumab exposure and sustained low-level IL-2 secretion to improved expansion and responses. The pivotal Phase 2 BALLI-01 and the Phase 1 NATHALI-01 studies are both open for recruitment, with key data readouts expected in Q4 2026.

Cellectis reported that the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy (RMAT) designation to lasmecabtagene timgedleucel (lasme-cel), its CD22‑targeting allogeneic CAR‑T cell therapy candidate for patients with relapsed or refractory B‑cell acute lymphoblastic leukemia. The company states this designation reflects FDA recognition of lasme‑cel’s potential to address unmet medical need, based on Phase 1 BALLI‑01 data showing promising efficacy and a manageable safety profile. Final Phase 1 BALLI‑01 data will be presented in an oral session at the 2026 European Hematology Association Congress on June 13. A pivotal Phase 2 portion of the BALLI‑01 trial is open for enrollment.

Cellectis S.A. is convening a combined general meeting of shareholders on June 25, 2026 in Paris to approve 2025 accounts, board renewals and extensive capital authorizations. The 2025 annual financial statements show a loss of 61,849,605 euros, while consolidated accounts show a loss of 67,592,758 US dollars. The loss will be allocated to retained earnings, which will then be cleared by transferring 61,849,605 euros from the share premium account, reducing it from 194,582,155.02 euros to 132,732,550.02 euros. Shareholders are asked to renew a share buyback program with a maximum unit price of 10 euros, a total cap of 10,000,000 euros and a limit of 10% of outstanding shares, with possible cancellation of up to 10% of capital every 24 months. Numerous resolutions would delegate to the board the power to issue new shares and securities, often with cancellation of preferential subscription rights, with aggregate nominal caps generally set at 2,514,775 euros (50% of current share capital of 5,029,549.70 euros) and debt issuance ceilings of up to 300,000,000 euros, including targeted issuances to sector investors, financing partners, development banks and via an at-the-market program in the U.S.

Cellectis S.A. has scheduled its annual shareholders general meeting for June 25, 2026 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. The formal notice and related meeting information are available on the company’s investor website.